Mural im La Mission District San Francisco (Aufnahme Oncoletter)
Trials in Progress Poster Session B: Urothelial Carcinoma
Link to POSTERS
Link to Posters: Sie müssen bei ASCO-GU eingeloggt sein und über eine aktuelle Registrierung verfügen, um auf die Poster dieser Sitzung zugreifen zu können. Hier können Sie die Registrierung erwerben.
ABLE-41: Nadofaragene firadenovec-vncg early use and outcomes in a real-world setting in the United States.
Presenter: Siamak Daneshmand, MD. USC/Norris Comprehensive Cancer Center, University of Southern California
The “Get Moving Trial”: A phase I/II RCT of home-based (P)rehabilitation ((P)REHAB) with ExerciseRx in muscle-invasive bladder cancer (MIBC)—Study protocol for a randomized controlled trial.
Presenter: Hanna Hunter, MD. Department of Rehabilitation Medicine, University of Washington, Fred Hutchinson Cancer Center
Intravesical recombinant BCG followed by perioperative chemo-immunotherapy for patients with muscle-invasive bladder cancer (MIBC): A multicenter, single arm phase 2 trial (SAKK 06/19).
Presenter: Richard Cathomas, MD. Division of Oncology, Cantonal Hospital Graubunden
New phase 1 SURPASS trial cohort: Early-line ADP-A2M4CD8 T-cell receptor T-cell therapy plus pembrolizumab in urothelial carcinoma.
Presenter: David H Aggen, MD, PhD. Memorial Sloan Kettering Cancer Center
A phase 1, first-in-human, dose-escalation and expansion study of FX-909 in patients with advanced solid malignancies, including advanced urothelial carcinoma.
Presenter: Gopa Iyer. Memorial Sloan Kettering Cancer Center
INVEST: A phase Ib window of opportunity study of atezolizumab administered either intravesically or direct tumour injection in patients with bladder cancer prior to radical cystectomy.
Presenter: Syed A. Hussain, MD. University of Sheffield and Sheffield Teaching Hospitals
Guiding adjuvant instillation in intermediate-risk non-muscle invasive bladder cancer by drug screens in patient-derived organoids.
Presenter: Martin Egger, MD. Spitalzentrum Biel
Neutralizing GDF-15 in muscle-invasive bladder cancer (MIBC): A neoadjuvant immunotherapy trial of visugromab (CTL-002) in combination with the anti-PD1 antibody nivolumab (GDFather-Neo).
Presenter: Andrea Necchi, MD. Vita-Salute San Raffaele University, IRCCS San Raffaele Hospital
Phase I/II study of ipilimumab plus nivolumab (IPI-NIVO) combined with sacituzumab govitecan in patients with metastatic cisplatin-ineligible urothelial carcinoma.
Presenter: Rohit K. Jain, MD, MPH. H. Lee Moffitt Cancer Center and Research Institute
MAIN-CAV: Phase III randomized trial of maintenance cabozantinib (CABO) and avelumab (Av) vs Av after first-line platinum-based chemotherapy in patients (pts) with metastatic urothelial cancer (mUC; Alliance A032001).
Presenter: Shilpa Gupta, MD. Cleveland Clinic Taussig Cancer Institute
PIVOT-006: A phase 3, randomized study of cretostimogene grenadenorepvec versus observation for the treatment of intermediate risk non-muscle invasive bladder cancer (IR-NMIBC) following transurethral resection of bladder tumor (TURBT).
Presenter: Robert S. Svatek, MD. UT Health San Antonio
A phase 1 study of IO102-IO103 vaccine plus pembrolizumab in patients with BCG-intolerant or unresponsive non-muscle invasive bladder cancer (NMIBC).
Presenter: Sumana Veeravelli, MD. University of California, Davis Comprehensive Cancer Center
Phase 3 open-label, randomized, controlled study of disitamab vedotin with pembrolizumab versus chemotherapy in patients with previously untreated locally advanced or metastatic urothelial carcinoma that expresses HER2 (DV-001).
Presenter: Matt D. Galsky, MD, FASCO. Icahn School of Medicine at Mount Sinai
WUTSUP-02-II-Neo-Dis-Tis: Investigating the efficacy and safety of neoadjuvant tislelizumab plus disitamab vedotin with adjuvant tislelizumab in upper urinary tract carcinoma—A phase II multi-center study.
Presenter: Yige Bao. Department of Urology, Institute of Urology, West China Hospital, Sichuan University
Pembrolizumab with favezelimab or vibostolimab for patients with bacillus Calmette-Guérin (BCG)–unresponsive high-risk (HR) non–muscle-invasive bladder cancer (NMIBC): Phase 2 KEYNOTE-057 cohort C.
Presenter: Girish S. Kulkarni, MD, PhD. University Health Network, Princess Margaret Cancer Centre, University of Toronto
Phase 3 KEYNOTE-992 study of pembrolizumab plus chemoradiotherapy versus placebo plus chemoradiotherapy in patients with muscle-invasive bladder cancer (MIBC).
Presenter: Shilpa Gupta, MD. Cleveland Clinic Taussig Cancer Institute
Phase 3 KEYNOTE-676 cohort A: Bacillus Calmette-Guérin (BCG) with or without pembrolizumab for high-risk (HR) non–muscle-invasive bladder cancer (NMIBC) that persists/recurs after BCG induction.
Presenter: Neal D. Shore, MD, FACS. Carolina Urologic Research Center
Efficacy and safety of the combination of cisplatin plus nab-paclitaxel and nivolumab with radiotherapy after maximal tumor resection in non-metastatic muscle invasive bladder cancer (CNN-BC trial).
Presenter: Chiara Ciccarese, MD, PhD. Fondazione Policlinico Universitario A. Gemelli, IRCCS